|Day Low/High||34.98 / 35.33|
|52 Wk Low/High||25.55 / 35.60|
European stocks rebounded with a bang Friday as recent central bank actions fell by the wayside and markets took heart from the latest bailout deal between Greece and the EU.
After Regulus dropped two of its drug programs, AstraZeneca ditched the duo's drug partnership, too.
AstraZeneca presented new data at the American Diabetes Association's (ADA) 77th Scientific Sessions underpinning the safety profile of Farxiga (dapagliflozin) with an analysis of data pooled from dapagliflozin clinical...
We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.
AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company's Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga...
AstraZeneca today reported further evidence that Tagrisso ® (osimertinib), the potential new standard of care for patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small...
European stocks slipped Monday as investors digested the latest terror attack in the U.K., continued concern over Spanish banks and a series of poorer-than-expected economic bulletins.
AstraZeneca plc said Monday that one of its new drugs has proven more effective than chemotherapy in treating a certain type of breast cancer.
U.K. Prime Minister Theresa May says technology companies have to do more to combat hate speech.
AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with...
Stocks are narrowly mixed on Friday, putting the S&P 500 and Nasdaq at risk of snapping a six-day winning streak.
AstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company's science-led strategy for transformational cancer medicine development at...
AstraZeneca today announced that the Company is notifying physicians and consumers that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of BRILINTA ®...
Jim Cramer focuses on Blackberry, Exact Sciences, Splunk, Freeport-McMoRan and more.
AstraZeneca today announced top-line results from the Phase IIIb/IV EXSCEL ( EX enatide S tudy of C ardiovascular E vent L owering) trial.
Jim Cramer says it's more than just the cloud. There are some astounding moves in the broader tech sector, too.
AstraZeneca shares edged higher Tuesday as investors shrugged off a mixed set of phase-3 results for the Anglo Swedish drug maker's Bydureon Exscel type II diabetes treatment.
Results from the Phase III ZONDA trial presented at the American Thoracic Society (ATS) 2017 International Congress demonstrated that adding benralizumab to standard of care allowed patients dependent on OCS to...
Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.
Novartis holds a 36.5% stake in the healthcare company.
Wall Street hold mixed through to the close Friday after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.
Stocks end the session mixed after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.
Stocks held mostly lower on Friday as better-than-expected numbers on U.S. retail sales put a June rate hike on the markets' radar.
Stocks held lower on Friday even after better-than-expected numbers on U.S. retail sales and consumer prices.
GlaxoSmithKline shares traded firmly higher Friday after one of its biggest shareholders said he was dumping his holding after fifteen years out of "frustration".
U.S. stock futures are slipping Friday ahead of data on consumer prices and retail sales and after the U.S. and China reach a trade deal.
Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.
Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?